An observational study in Cancer Pain, Renal Insufficiency Chronic and Hydromorphone Use, sponsored by Taian Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Taian Cancer Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.
Among the 31 studies in Cancer Pain with a site in China, this one is one of 5 that started in 2026, is one of 7 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 26th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:
Qinghai Red Cross Hospital · Sites in China
Ages 18–80
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
The Third Affiliated hospital of Zhejiang Chinese Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 151 across 61 observational studies indexed under Cancer Pain.
Median enrollment 110 across the 24 interventional studies, 200 across the 7 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Taian Cancer Hospital is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Taian Cancer Hospital has 1 study filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Cancer Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07657390Cancer Institute and Hospital, Chinese Academy of Medical SciencesProspective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain | 2026-12-31 |
| NCT07869797Mundipharma (China) Pharmaceutical Co. LtdReal-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Cancer Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study aims to understand whether domestic hydromorphinone sustained-release tablets are effective and safe in treating moderate to severe cancer pain in elderly patients with renal insufficiency.
It will also understand key safety concerns, especially regarding renal function and neurotoxicity.
The main questions it aims to answer include:1. Can hydromorphinone sustained-release tablets effectively relieve the pain of such patients and improve their quality of life?2. During the treatment period, what effect does this drug have on renal function (measured by eGFR)? 3. In this specific population, what are the occurrence and characteristics of neurotoxicity and other side effects induced by opioids? Researchers will compare elderly cancer pain patients with renal insufficiency with those with normal renal function (both receiving the study drug treatment) to observe whether there are differences in efficacy and safety results.
Participants will:
Receive a standardized treatment plan: First, subcutaneous injection of hydromorphinone injection for dose titration, and then switch to daily oral administration of hydromorphinone sustained-release tablets for 4 weeks.
Visit the clinic for assessment and examination (including renal function tests) during the baseline period, on the 7th day, and at the weekends of the 2nd, 3rd, and 4th days.
Regularly monitor and record the degree of pain, the occurrence of explosive pain, the use of medication, and any side effects.
The research design and methodology described in this study using prospective, observational cohort design. Unlike randomized controlled trials, this study aims to observe the natural outcomes of standardized treatment regimens in elderly patients with different renal function statuses under real-world conditions. All eligible patients enrolled in the group will receive a unified analgesic treatment plan based on international authoritative guidelines: Firstly, subcutaneous injection titration of hydromorphinone injection will be performed to quickly determine the individualized dose required for pain control; After the pain stabilized, it was uniformly converted to the same dose of domestic hydromorphinone sustained-release tablets for oral maintenance treatment once daily. The total treatment observation period was 4 weeks.
The key to the research lies in "hierarchical comparison". Before treatment, the investigators will naturally divide the patients into two cohorts based on their estimated glomerular filtration rate (eGFR, a core indicator for evaluating renal function) : the "Elderly with renal insufficiency group" and the "Elderly with normal renal function Group". In this way, the investigators can directly compare the performance differences of the drug in these two types of people with different physiological states.
The sample size calculation (planned to include a total of 62 patients) was based on the primary safety endpoint - the change in eGFR values relative to baseline at week 4 of treatment. A clinically significant effect size was preset during the calculation, and sufficient statistical certainty was ensured to guarantee the reliability of the research results.
The core assessment and monitoring framework in addition to conventional pain intensity assessment (NRS) adopting digital grading method, quality of living survey and common adverse reactions, this research established dual core security monitoring system:
Dynamic monitoring of renal function: Serum creatinine will be systematically detected and eGFR calculated at five time points before and during treatment. This is not only used to compare the differences between groups, but more importantly, to monitor the dynamic trajectory of each patient's individual renal function and promptly detect any clinically significant signs of deterioration.
Active screening for neurotoxicity (OIN) : In response to neurotoxic symptoms such as delirium, drowsiness, and myoclonus that may be caused by opioids, the study will conduct active screening and assessment once a week using a series of standardized scales, for example, using the Confusion Assessment method (CAM) to screen for delirium. This systematic monitoring aims to capture the incidence and characteristics of OIN more precisely.
Direct evidence: It provides the first prospective efficacy and safety data for the application of domestic hydromoradone sustained-release tablets in elderly patients with renal insufficiency.
Clinical guidance: Clarify the adverse reaction spectrum of this drug in this population, especially its specific effects on renal function and the nervous system, to provide a basis for clinical dose adjustment and risk early warning.
Methodological demonstration: Demonstrate how to answer practical questions about medication safety for specific high-risk populations through rigorous observational studies and advanced statistical methods.
Through this research, the investigators hope to provide decision support based on localized drugs and high-level evidence for clinicians when treating this complex and vulnerable patient group, ultimately promoting the precision and safety improvement of cancer pain management in the elderly.
Study participants will be selected from the patient population presenting at the Oncology Department of Taian City Tumor Hospital, a regional tertiary cancer care center in Shandong Province, China. Recruitment will specifically target older adult patients with cancer who are being evaluated for and initiate standardized opioid therapy for moderate-to-severe cancer pain at this institution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1)Mild-to-moderate renal insufficiency group: 30 mL/min/1.73m² ≤ estimated (eGFR) \< 90 mL/min/1.73m².
2)Normal renal function group: eGFR ≥ 90 mL/min/1.73m². 5.Expected survival period ≥ 3 months. 6.Ability to take oral medication and cooperate with study assessments. 7.Willing to participate voluntarily and able to provide signed .
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elder cancer pain patients with mild to moderate renal insufficiency at enrollment, defined by an estimated glomerular filtration rate (eGFR) range of 30 ≤ eGFR \< 90 mL/min/1.73m². They receive standardized Hydromorphone Sustained-Release Tablet treatment.
Elder cancer pain patients with normal renal function at enrollment, defined by an estimated glomerular filtration rate (eGFR) of eGFR ≥ 90 mL/min/1.73m². They receive the identical standardized Hydromorphone Sustained-Release Tablet treatment as Cohort 1, serving as the reference comparison group.
The changes in estimated glomerular filtration rate (eGFR) from baseline at the end of the 4th week of treatmentDetailed
The estimated glomerular filtration rate (eGFR) is a validated indicator of kidney function. It is calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which incorporates the patient's age and sex. All values are normalized to body surface area and expressed as mL/min/1.73m². On this scale, higher eGFR values indicate better kidney function, while lower values indicate impaired kidney function. The change in eGFR is defined as the value measured at week 4 minus the value measured at baseline (immediately prior to treatment initiation). A negative change value indicates a decrease in eGFR from baseline, representing a decline in kidney function. A positive change value indicates an increase in eGFR from baseline, representing an improvement in kidney function. eGFR is measured from venous blood samples collected at baseline and at week 4.
Time frame: From the start of maintenance treatment with hydromorphinone sustained-release tablets until the end of the fourth week of treatment.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data that underlie the results reported in the primary publication (including demographics, baseline clinical characteristics, serial eGFR measurements, pain scores, and safety outcomes) will be shared. Supporting documents like the study protocol and statistical analysis plan will also be provided. Data will become available 12 months after article publication to researchers who submit a methodologically sound proposal and sign a data use agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Start Date :12 months after the publication of the primary study results in a peer-reviewed journal. End Date : 5 years after the IPD sharing start date.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.
Of 26 observational studies under Cancer Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 34 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taian Cancer Hospital